文献速递乳腺癌

基于2周来曲唑后Ki67应答对HR+/HER2+乳腺癌患者降阶梯治疗:PerELISA新辅助研究结果

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
PubMed 文献 · Ann Oncol · 2019-01-01

PerELISA是一项II期多中心研究,入组绝经后HR+/HER2+可手术乳腺癌患者,先接受2周来曲唑,Ki67相对下降>20%者为分子应答者,继续来曲唑联合曲妥珠单抗-帕妥珠单抗5周期;分子无应答者接受每周紫杉醇13周联合曲妥珠单抗-帕妥珠单抗。64例入组,44例为分子应答者,其中9/44(20.5%,95%CI 11.1%-34.5%)达到乳腺及腋窝pCR,主要终点达到。

要点

  • 2周来曲唑后Ki67相对下降>20%的HR+/HER2+患者,免化疗方案pCR率达20.5%。
  • 分子应答者中HER2富集型pCR率45.5%显著高于其他亚型13.8%(P=0.042)。
  • PAM50内在亚型与Ki67应答及pCR显著相关。

核心结论

  • 研究达到主要终点,在短期来曲唑后经Ki67下降筛选的患者中,免化疗可获得有意义的pCR率。
  • PAM50内在亚型分型进一步细化识别可免除化疗的患者亚群的能力。

研究设计与样本

  • PerELISA为II期多中心研究,入组绝经后HR+/HER2+可手术乳腺癌患者。
  • 患者先接受2周来曲唑,再活检评估Ki67;分子应答者(Ki67相对下降>20%)继续来曲唑联合曲妥珠单抗-帕妥珠单抗5周期;分子无应答者接受每周紫杉醇13周联合曲妥珠单抗-帕妥珠单抗。
  • 主要终点为乳腺及腋窝pCR;采用两阶段Simon设计,需至少8/43例pCR以拒绝无效假设。
  • 共入组64例,44例为分子应答者。

主要发现

  • 44例分子应答者均完成来曲唑-曲妥珠单抗-帕妥珠单抗治疗并接受手术,9/44例达到pCR(20.5%,95%CI 11.1%-34.5%)。
  • 分子无应答者中16/17例完成治疗并接受手术,pCR率为81.3%。
  • PAM50内在亚型与Ki67应答及pCR显著相关。
  • 分子应答者中HER2富集型pCR率显著高于其他亚型(45.5% vs 13.8%,P=0.042)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower pathologic complete response (pCR) rates in hormone receptor (HR) positive versus negative tumors. The PerELISA study was aimed to evaluate the efficacy of a de-escalated, chemotherapy-free neoadjuvant regimen in HR+/HER2+ breast cancer patients selected on the basis of Ki67 inhibition after 2-week letrozole. PATIENTS AND METHODS: PerELISA is a phase II, multicentric study for postmenopausal patients with HR+/HER2+ operable breast cancer. Patients received 2-week letrozole, and then underwent re-biopsy for Ki67 evaluation. Patients classified as molecular responders (Ki67 relative reduction >20% from baseline) continued letrozole and started trastuzumab-pertuzumab for five cycles. Patients classified as molecular non-responders started weekly paclitaxel for 13 weeks combined with trastuzumab-pertuzumab. Primary aim was breast and axillary pCR. According to a two-stage Simon's design, to reject the null hypothesis, at least 8/43 pCR had to be documented. RESULTS: Sixty-four patients were enrolled, 44 were classified as molecular responders. All these patients completed the assigned treatment with letrozole-trastuzumab-pertuzumab and underwent surgery. A pCR was observed in 9/44 cases (20.5%, 95% confidence interval 11.1% to 34.5%). Among molecular non-responders, 16/17 completed treatment and underwent surgery, with pCR observed in 81.3% of the cases. PAM50 intrinsic subtype was significantly associated with Ki67 response and pCR. Among molecular responders, the pCR rate was significantly higher in HER2-enriched than in other subtypes (45.5% versus 13.8%, P = 0.042). CONCLUSIONS: The primary end point of the study was met, by reaching the pre-specified pCRs. In patients selected using Ki67 reduction after short-term letrozole exposure, a meaningful pCR rate can be achieved without chemotherapy. PAM50 intrinsic subtyping further refines our ability to identify a subset of patients for whom chemotherapy might be spared. EUDRACT NUMBER: 2013-002662-40. CLINICALTRIALS.GOV IDENTIFIER: NCT02411344.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Guarneri V, Dieci MV, Bisagni G, et al. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Ann Oncol. 2019. PMID: 30778520. doi:10.1093/annonc/mdz055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。